{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"125","value":"18.6"},{"groupId":"OG001","spread":"513","value":"58.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"172"}],"units":"Participants"}],"title":"Cycle 1 Day 1: pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2400","value":"1640"},{"groupId":"OG001","spread":"1790","value":"1190"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 0.5 hours post dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3680","value":"6860"},{"groupId":"OG001","spread":"2100","value":"4090"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 1.5 hours post dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2010","value":"3400"},{"groupId":"OG001","spread":"925","value":"1850"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"142"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 4 to 8 hours post dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"468","value":"119"},{"groupId":"OG001","spread":"405","value":"73.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"title":"Cycle 2 Day 1: pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"697","value":"150"},{"groupId":"OG001","spread":"256","value":"53.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"Cycle 3 Day 1: pre-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"172"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received 450 milligram (mg) of LGX818 orally once daily (QD) along with 45 mg of MEK162 twice daily (BID) for each 28 day treatment cycle until progressive disease (PD) as confirmed by Blinded Independent Review Committee (BIRC), withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG000","title":"Part 1:LGX818 450 mg QD+MEK162 45 mg BID (Combo 450)"},{"description":"Participants received 300 mg of LGX818 orally once daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG001","title":"Part 1: LGX818 300 mg"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analysis set included all participants who received at least one dose of LGX818 or MEK162 and had at least one evaluable post-baseline LGX818 or MEK162 concentration measurement. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure and \"Number analyzed\" signifies participants evaluable for each specified category at each specified row.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: pre-dose, 0.5, 1.5, 4 to 8 hours post dose; Cycle 2 Day 1: pre-dose; Cycle 3 Day 1: pre-dose","title":"Part 1: Plasma Concentrations of LGX 818","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}